Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: Prospective, randomized, crossover trial

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 2, 2007, Pages 456-461

  Banaszewska, Beata ^a   Pawelczyk, Leszek ^a   Spaczynski, Robert Z ^a   Dziura, James ^b   Duleba, Antoni J ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DESOGESTREL PLUS ETHINYLESTRADIOL; FOLLITROPIN; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROLACTIN; SIMVASTATIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER FUNCTION TEST; LUTEINIZING HORMONE BLOOD LEVEL; MUSCLE INJURY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33847004030     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1988     Document Type: Article

References (48)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-4011
3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
4. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS 2006 Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91:1357-1363
5. Holte J, Gennarelli G, Wide L, Lithell H, Berne C 1998 High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 83:1143-1150
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
7. Wild RA, Applebaum-Bowden D, Demers LM, Bartholomew M, Landis JR, Hazzard WR, Santen RJ 1990 Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgens. Clin Chem 36:283-289
8. Mahabeer S, Naidoo C, Norman RJ, Jialal I, Reddi K, Joubert SM 1990 Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res 22:537-540
9. Dahlgren E, Johansson S, Lindsted G, Knutsson F, Oden A, Janson P, Mattson L-A, Crona N, Lundberg P-A 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57:505-513
10. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 71:599-604
11. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595-600
12. Wild R 2002 Long-term health consequences of PCOS. Hum Reprod Update 8:231-241
13. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
14. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C 2004 Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89:5592-5596
15. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, Janssen OE 2003 Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:5801-5807
16. Azziz R, Marin C, Hoq L, Badamgarav E, Song P 2005 Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90:4650-4658
17. Liao JK 2005 Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F-33F
18. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG 1992 Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 41:229-235
19. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G 2002 Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300-305
20. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K 2000 Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043-1046
21. Engelhardt H, Gore-Langton RE, Armstrong DT 1989 Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of the 17 α-hydroxylase:C-17,20-lyase complex. Endocrinology 124:2297-2304
22. Spicer LJ, Hamilton TD, Keefer BE 1996 Insulin-like growth factor I enhancement of steroidogenesis by bovine granulosa cells and thecal cells: dependence on de novo cholesterol synthesis. J Endocrinol 151:365-373
23. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ 2004 Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82(Suppl 3):1193-1197
24. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L 2006 Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85:996-1001
25. 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25
26. Balen AH, Laven JS, Tan SL, Dewailly D 2003 Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9:505-514
27. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
28. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ 2000 Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410
29. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
30. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F 1976 Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57:1320-1329
31. Kazer RR, Kessel B, Yen SS 1987 Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome. J Clin Endocrinol Metab 65:233-236
32. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L 2003 Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels. Fertil Steril 79:1008-1014
33. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC 2000 Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 85:4047-4052
34. Chiloeches A, Lasa M, Brihuega F, Montes A, Toro MJ 1995 Effects of lovastatin on adenylyl cyclase activity and G proteins in GH4C1 cells. FEBS Lett 361:46-50
35. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB 1985 Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946-951
36. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS 1992 Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 37:119-125
37. Holte J, Bergh T, Berne C, Lithell H 1994 Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 41:463-471
38. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson Jr SK 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174:1224-1229
39. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414-2421
40. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D 2006 Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21:1426-1431
41. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565
42. Ridker PM, Buring JE, Cook NR, Rifai N 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107:391-397
43. Cybulsky MI, Gimbrone Jr MA 1991 Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788-791
44. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE 1993 Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 92:945-951
45. Guzick DS 2004 Polycystic ovary syndrome. Obstet Gynecol 103:181-193
46. Hillard PJ 2005 Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am 34:707-723
47. Edison RJ, Muenke M 2004 Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 131:287-298
48. Edison RJ, Muenke M 2004 Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350:1579-1582